Barinthus BiotherapeuticsNASDAQ: BRNS

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.

Barinthus Biotherapeutics is in the Healthcare sector

Barinthus Biotherapeutics is in the Biotechnology industry

Barinthus Biotherapeutics is headquartered in United Kingdom

Barinthus Biotherapeutics initial public offering (IPO) was on 30 April 2021

https://www.barinthusbio.com

No, Barinthus Biotherapeutics is not included in the S&P 500 index

No, Barinthus Biotherapeutics is not included in the NASDAQ 100 index

No, Barinthus Biotherapeutics is not included in the Dow Jones index